NovImmune
discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer... Read moreNovImmune
discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer... Read more
News
Feb 20, 2020
startupticker
NovImmune: Novimmune's successor company receives milestone payment from Takeda
Jun 13, 2019
BioPortfolio
NovImmune: Sobi acquire Novimmune in deal worth more than £400 million httpbit.ly31xbFeS pharma biotech immunologypic.twitter.commUGnxDDLJC
Jun 13, 2019
BioCentury
NovImmune: Sobi buying Novimmune assets as it refocuses R&D
Jun 12, 2019
Reuters
NovImmune: Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology
Mar 26, 2019
Pharmabiz
NovImmune: Sobi, Novimmune select Honourees for 2019 NORD Rare Impact Award for Gamifant
Dec 04, 2018
PR Newswire
Press Release: NovImmune : Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH
Nov 23, 2018
BioPortfolio
NovImmune: Sobi Novimmune announce US FDA approves Gamifant to treat primary HLH
Nov 22, 2018
Cision
NovImmune: Late-breaking abstract at ASH supports evidence on transformative first-ever treatment in primary HLH
Aug 25, 2018
Pharmabiz
NovImmune: Sobi acquires global rights for emapalumab from Novimmune
Aug 23, 2018
startupticker
NovImmune: Novimmune's lead drug on the way to the market
NovImmune Competitors
1
2
3
4
5
6
7
8
9